ANIP: Q2 2026 delivered 26% revenue growth, led by Rare Disease and Cortrophin Gel's 43% surge
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 26% revenue growth and 32% higher adjusted EBITDA, driven by Rare Disease and generics. Cortrophin Gel led with 43% growth, and guidance for 2026 was reaffirmed, projecting strong top- and bottom-line expansion.Original document: ANI Pharmaceuticals, Inc. [ANIP] Slides Release — Aug. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 26% revenue growth and 32% higher adjusted EBITDA, driven by Rare Disease and generics. Cortrophin Gel led with 43% growth, and guidance for 2026 was reaffirmed, projecting strong top- and bottom-line expansion.
Original document: ANI Pharmaceuticals, Inc. [ANIP] Slides Release — Aug. 7 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.